BiotechTube

KHK6188 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postherpetic Neuralgia

Conditions

Postherpetic Neuralgia

Trial Timeline

Feb 1, 2012 → Jun 1, 2013

NCT ID
NCT01544296

About KHK6188 + Placebo

KHK6188 + Placebo is a phase 2 stage product being developed by Kyowa Kirin for Postherpetic Neuralgia. The current trial status is completed. This product is registered under clinical trial identifier NCT01544296. Target conditions include Postherpetic Neuralgia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01544296Phase 2Completed

Competing Products

20 competing products in Postherpetic Neuralgia

See all competitors
ProductCompanyStageHype Score
QUTENZAAstellas PharmaApproved
85
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
77
MK-8291 + PlaceboMerckPhase 1
33
Etoricoxib + PlaceboMerckApproved
85
ADL5747 + Placebo + PregabalinMerckPhase 2
52
MK0759MerckPhase 2
52
MK0686MerckPhase 2
52
Comparator: pregabalin + Comparator: Placebo (unspecified)MerckPhase 1
33
Lyrica (pregabalin) + PlaceboPfizerApproved
84
RN624 + RN624 + PlaceboPfizerPhase 2
51
T-62PfizerPhase 2
51
pregabalin + pregabalin/PF-00489791 + PlaceboPfizerPhase 2
51
PH-797804 + PlaceboPfizerPhase 2
51
Placebo + Pregabalin + Pregabalin + PregabalinPfizerPhase 3
76
pregabalinPfizerPhase 3
76
pregabalinPfizerApproved
84
T-62 Dose 1 + T-62 Dose 2PfizerPhase 2
51
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BIDHaisco Pharmaceutical GroupPhase 3
74
LevetiracetamUCBPhase 2
49

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85